Alfuzosin


Alfuzosin
Systematic (IUPAC) name
N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
Identifiers
CAS number	81403-80-7
ATC code	G04CA01
PubChem	2092
DrugBank	APRD00490
Chemical data
O₄
Mol. mass	389.449 g/mol
Pharmacokinetic data
Bioavailability	49%
Protein binding	82%-90%
CYP3A4-mediated)
Half life	10 hours
Excretion	Fecal (69%) and renal (24%)
Therapeutic considerations
Pregnancy cat.	B2(AU) B(US)
Legal status	℞-only(US)
Routes	Oral

Alfuzosin (INN, provided as the hydrochloride salt) is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate.

Alfuzosin is marketed by Sanofi Aventis under the brand name Uroxatral. Alfuzosin was approved by the FDA for treatment of BPH in June 2003.

Side effects

The most common side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.

Contraindications

Alfuzosin should be used with caution in patients with severe renal insufficiency, and should not be prescribed to patients with a known history of QT prolongation or to patients who are taking medications known to prolong the QT interval.

v • d • e Urologicals (Finasteride Terazosin **Herbals: Pygeum africanum, Serenoa repens**

Categories: Quinazolines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Alfuzosin". A list of authors is available in Wikipedia.